Abstract
Aim The goal of this study was to analyze the expression of human kallikrein 11 (hK11) in low rectal carcinoma (LRC) tissues, as well as its association with the clinicopathologic features of LRC patients and its prognostic significance. Methods Between January 1998 and January 2003, 126 patients with LRC were randomized to receive laparoscopic-assisted abdominoperineal resection (APR). Their hK11 expression levels were examined by immunostaining on paraffin-embedded tumor specimens. Then the association of hK11 expression with clinicopathologic characteristics and patients’ prognosis was analyzed. Results The positive degree of immunohistochemical staining in cancerous tissues (1.86 ± 0.02) was higher than that in the control group (1.18 ± 0.11, P = 0.008). Strong positive hK11 staining associated significantly with various clinicopathologic features, such as Dukes Staging (P < 0.001), histological differentiation grade (P = 0.003), CEA level (P = 0.01), lymph node metastasis (P < 0.001), and invasion depth (P = 0.002). Patients with weak hK11 positive expression showed better survival rates of 5-year follow-up than those with strong positive expression (80.85% for weak positive expression and 58.23% in strong positive expression, respectively; P < 0.01 for analyses). Using Cox regression analysis of the 126 patients, strong positive expression of hK11, Dukes Staging, lymph node metastasis, and invasion depth seemed to be independent prognostic indicators (P < 0.01, P = 0.02, P < 0.01 and P < 0.01, respectively). Conclusion hK11 may be another prognostic biomarker of LRC. Knowledge of hK11 expression in LRC tissues could contribute to the prediction of prognosis of LRC patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- LRC:
-
Low rectal carcinoma
- hK11:
-
Human kallikrein 11
- KLK11:
-
Human kallikrein gene 11
- APR:
-
Abdominoperineal resection
References
Kane JM, Petrelli NJ. Controversies in the surgical management of rectal cancer. Semin Radiat Oncol. 2003;13:403–18. doi:10.1016/j.semradonc.2003.07.001.
Kapiteijn E, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46. doi:10.1056/NEJMoa010580.
Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358:1291–304. doi:10.1016/S0140-6736(01)06409-1.
Fernando SC, Buck JS, Ashworth MD. Porcine endometrial and conceptus tissue kallikrein 1, 4, 11, and 14 gene expression. Reproduction. 2006;132:939–47. doi:10.1530/rep.1.01013.
Nakamura T, Mitsui S, Okui A. Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate. Prostate. 2003;54:299–305. doi:10.1002/pros.10191.
Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res. 2004;2:257–80.
Shigemasa K, Gu L, Tanimoto H. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res. 2004;10:2766–70. doi:10.1158/1078-0432.CCR-03-0269.
Yoshida S, Taniguchi M, Suemoto T. cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta. 1998;1399:225–8.
Stavropouloua P, Gregorakisb AK. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta. 2005;357:190–5. doi:10.1016/j.cccn.2005.03.026.
Nakamura T, Scorilas A, Stephan C. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 2003;63:6543–6.
Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204. doi:10.1210/er.22.2.184.
Luo L, Bunting P, Scorilas A. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta. 2001;306:111–8. doi:10.1016/S0009-8981(01)00401-6.
Tanimoto H, Underwood LJ, Shigemasa K. Increased expression of protease M in ovarian tumors. Tumour Biol. 2001;22:11–8. doi:10.1159/000030150.
Yousef GM, Polymeris M-E, Yacoub GM. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003;63:2223–7.
Obiezu CV, Scorilas A, Katsaros D. Higher human kallikrein gene 4 (klk4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res. 2001;7:2380–6.
Kim H, Scorilas A, Katsaros D. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001;84:643–50. doi:10.1054/bjoc.2000.1649.
Yousef GM, Kyriakopoulou LG, Scorilas A. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 2001;61:7811–8.
Petraki CD, Karavana VN, Skoufogiannis PT. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001;49:1431–41.
Dong Y, Kaushal A, Bui L. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res. 2001;7:2363–71.
Magklara A, Scorilas A, Katsaros D. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001;7:806–11.
Acknowledgment
The project was supported by Hunan Provincial Natural Science Foundation of China, Project Number is 06JJ20089.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, X., Tang, H.Y., Li, X.R. et al. Over-expression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma. Med Oncol 27, 40–44 (2010). https://doi.org/10.1007/s12032-009-9167-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-009-9167-2